Dexcom announced today that the US Food and Drug Administration has greenlighted its 15-day G7 continuous glucose monitoring system (CGM), despite an outstanding warning letter. The new sensor is expected to launch in the second half of this year, which will give Dexcom time to focus on sensor integration with automated insulin delivery partners, the company said.
The San Diego-based diabetes company announced on 10 March that the FDA cleared its 15-day G7 CGM, which will be...